NicOx S.A.
Research NicOx S.A. (ALCOX) on Bullrun: market cap EUR 37.48M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALCOX
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 37.48M
- Financial periodFY2025
- RevenueEUR 16.77M
- Revenue growth113.4%
- Net income-EUR 2.41M
- Gross margin39.0%
Valuation Snapshot
latest market cap is EUR 37.48M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 16.77M | -EUR 2.41M | n/a | 39.0% | -0.03 | EUR 4.15M | EUR 406.33K | EUR 6.02M |
| FY2024 | EUR 7.86M | -EUR 22.39M | n/a | 85.9% | -0.35 | EUR 10.54M | EUR 17.74M | EUR 3.41M |
| FY2023 | EUR 6.90M | -EUR 20.88M | n/a | -170.4% | -0.42 | EUR 11.26M | EUR 25.79M | EUR 21.41M |
| FY2022 | EUR 5.24M | -EUR 31.29M | -EUR 23.17M | -245.3% | -0.62 | EUR 27.08M | EUR 25.30M | EUR 42.29M |
| FY2021 | EUR 8.58M | -EUR 43.76M | -EUR 18.49M | 84.3% | -1.17 | EUR 41.97M | EUR 21.51M | EUR 75.55M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 37.48M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About NicOx S.A.
Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. It develops solutions to preserving vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NicOx S.A.'s market cap?
NicOx S.A.'s market capitalization is EUR 37.48M.
What does NicOx S.A. do?
Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. It develops solutions to preserving vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.